Takaaki Sawada

Takaaki Sawada

Auto-generated profile, based on publicly available information

Takaaki Sawada

Department of Pediatrics Kumamoto University Hospital Kumamoto Japan

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2020 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
TSTakaaki Sawada
Takaaki Sawada
JKJun-ichi Kido
Jun-ichi Kido
KSKeishin Sugawara
Keishin Sugawara
SMShirou Matsumoto
Shirou Matsumoto
FTFumio Takada
Fumio Takada
KNKimitoshi Nakamura
Kimitoshi Nakamura
Background: In Japan, newborn and high‐risk screening for Fabry disease (FD), an inherited X‐linked disorder caused by GLA mutations, using dried blood spots was initiated in 2006. In newborn screening, 599,711 newborns were screened by December 2018, and 57 newborns from 54 families with 26 FD‐associated variants were detected. In high‐risk screening, 18,235 individuals who had symptoms and/or a family history of FD were screened by March 2019, and 236 individuals from 143 families with 101 FD‐associated variants were detected. Totally 3, 116 variants were detected; 41 of these were not registered in Fabry‐database.org or ClinVar and 33 were definitely novel. Herein, we report the clinical outcomes and discuss the pathogenicity of the 41 variants.Methods: We traced nine newborns and 46 individuals with the 33 novel variants, and nine newborns and 10 individuals with eight other variants not registered in the FD database, and analyzed the information on symptoms, treatments, and outcomes.Results: Thirty‐eight of the 46 individuals with the 33 novel variants showed symptoms and received enzyme‐replacement therapy and/or chaperone treatment.Conclusion: Delayed diagnosis should be avoided in patients with FD. Our results will help clinicians diagnose FD and determine the appropriate treatment for patients with these variants.

1 January 1998 in Chemical and Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
MKMasaya Kawase
Masaya Kawase
TSTakaaki Sawada
Takaaki Sawada
KYKiyohito Yagi
Kiyohito Yagi
TMTadashi Mizoguchi
Tadashi Mizoguchi
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

20 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
YKYuya Kinoshita
Yuya Kinoshita
JKJun-ichi Kido
Jun-ichi Kido
TSTakaaki Sawada
Takaaki Sawada
KSKeishin Sugawara
Keishin Sugawara
SYShinichiro Yoshida
Shinichiro Yoshida
KNKimitoshi Nakamura
Kimitoshi Nakamura
BackgroundPompe disease (PD), a lysosomal storage disorder, is caused by acid α-glucosidase (GAA) deficiency. Newborn screening (NBS) enables early PD diagnosis and enzyme replacement therapy (ERT) initiation, particularly in infantile-onset Pompe disease (IOPD). However, the clinical significance of GAA variants identified by NBS remains uncertain because of limited long-term follow-up data.MethodsBetween April 2013 and March 2025, 492,091 newborns in the Kumamoto and Fukuoka prefectures of Japan underwent PD NBS using dried blood spot-based GAA assays. The screening protocol was sequentially optimized using three assay methods (Methods I, II, and III). Newborns with persistently low GAA activity underwent clinical evaluations and were offered GAA gene sequencing. Long-term clinical follow-up data of screening-positive individuals were retrospectively analyzed, and the clinical significance of the identified GAA variants was evaluated.ResultsA total of 492,091 newborns underwent PD-NBS between 2013–2025. The complex allele c.[752C>T;761C>T] was reclassified as nonpathogenic, further resulting in the reclassification of six individuals previously considered as potential late-onset Pompe disease (LOPD) carriers or potential carriers. Two infants with IOPD and one with potential LOPD were identified. Both patients with IOPD received early ERT with favorable systemic outcomes during follow-up, although one patient developed progressive central nervous system abnormalities. The individual classified as having potential LOPD remained clinically asymptomatic during the approximate 7-year follow-up period.ConclusionsPD NBS has enabled early the diagnosis and treatment of clinically significant PD in Japan. Long-term follow-up facilitated GAA variant re-evaluation and highlighted the potential for neurological complications despite favorable systemic ERT responses.

27 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
YKYuya Kinoshita
Yuya Kinoshita
JKJun-ichi Kido
Jun-ichi Kido
TSTakaaki Sawada
Takaaki Sawada
KSKeishin Sugawara
Keishin Sugawara
SYShinichiro Yoshida
Shinichiro Yoshida
KNKimitoshi Nakamura
Kimitoshi Nakamura
Background: Gaucher disease (GD) encompasses a broad clinical spectrum ranging from non-neuronopathic to severe neuronopathic forms. Although newborn screening (NBS) for GD has been implemented in several regions worldwide, long-term outcome data for patients with neuronopathic GD remain limited. Therefore, we evaluated the clinical characteristics, genotypes, treatments, and long-term outcomes of patients with GD identified through a regional population-based NBS program in Japan.,Methods: We retrospectively analyzed patients diagnosed with GD through a regional population-based NBS program in Japan between 2016 and 2025. Screening was based on the glucocerebrosidase activity in dried blood spots, with confirmatory clinical, biochemical, and genetic evaluations.,Results: Among the 341,029 newborns screened, 17 (0.0050%) were recalled for repeat testing, and seven were diagnosed with GD. Compared with our previous report, one patient was reclassified from GD3 to classic GD2 during the extended follow-up. Consequently, the final cohort included one patient with GD1, three with GD2, two with GD3, and one unclassified. Enzyme replacement therapy (ERT) was initiated in all patients. The patient with GD1 remained clinically stable during follow-up. All patients with GD2 died despite treatment. Patients with GD3 developed slow horizontal saccades but showed improvement in hematological and visceral manifestations under ERT.,Conclusions: A regional population-based NBS approach enabled identifying patients with a broad and evolving phenotypic spectrum of GD. Long-term follow-up is important for accurate disease classification and reclassification. Although current therapies for neuronopathic diseases are inefficient, NBS allows early diagnosis and longitudinal clinical monitoring.

25 September 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
JKJun-ichi Kido
Jun-ichi Kido
KYKousei Yurinaga
Kousei Yurinaga
FNFumiko Nozaki
Fumiko Nozaki
NYNaomi Yano
Naomi Yano
KSKeishin Sugawara
Keishin Sugawara
KNKimitoshi Nakamura
Kimitoshi Nakamura
Background: Fukuyama congenital muscular dystrophy (FCMD) and glycogen storage disease type Ia (GSD Ia) are autosomal recessive disorders for which early diagnosis is increasingly important because of emerging disease-modifying therapies. The FKTN 3-kb SVA insertion and G6PC1 c.648G>T account for large proportions of disease-associated alleles in Japanese patients. We developed targeted newborn screening assays for these variants using dried blood spots (DBSs).,Methods: The FKTN c.*4392_*4393ins[AB185332.1] variant was analyzed using a SYBR Green-based real-time PCR assay with wild-type and insertion-specific primer pairs, whereas G6PC1 c.648G>T was analyzed using a TaqMan genotyping assay. The assays were evaluated using DBS samples from 1,055 newborns and five genetically confirmed homozygous patients with each disorder. Heterozygous and homozygous results were confirmed by Sanger sequencing.,Results: Both assays distinguished variant-negative, heterozygous, and homozygous genotypes using DNA extracted from a single 3.2-mm DBS punch. Among the 1,055 newborns, 11 were heterozygous for the FKTN variant and five were heterozygous for the G6PC1 variant; no homozygous newborns were identified. All heterozygous newborn samples and all homozygous patient samples were confirmed by Sanger sequencing. The allele frequencies were 0.00521 and 0.00237, respectively, corresponding to observed carrier frequencies of 1.04% (95% CI, 0.52–1.86%) and 0.47% (95% CI, 0.15–1.10%).,Conclusions: These DBS-based real-time PCR assays enable rapid, targeted detection of two clinically relevant pathogenic variants prevalent in Japan and may provide a practical first-tier molecular screening approach for FCMD and GSD Ia. Comprehensive confirmatory genetic testing and larger prospective studies are required before population-wide implementation.

18 August 2026 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
NKNobuhiko Koga
Nobuhiko Koga
HYHiroaki Yodogawa
Hiroaki Yodogawa
TSTakaaki Sawada
Takaaki Sawada
YMYuichi Mushimoto
Yuichi Mushimoto
SNShinichiro Nagamitsu
Shinichiro Nagamitsu
TITakahito Inoue
Takahito Inoue
We described a 12‐year‐old boy with classic Fabry disease who was diagnosed through newborn screening. At age 6.2, he started agalsidase alfa based on evidence of subclinical organ involvement. At age 7.2, acroparesthesia subsequently developed. At age 10.9, after switching to agalsidase beta due to an insufficient clinical and biochemical response, his acroparesthesia resolved and plasma Lyso‐Gb3 decreased. This report broadens the clinical understanding of children with Fabry disease.